Trebananib combined with paclitaxel improved survival by a month compared to the placebo, from 18.3 months to 19.3 months.
said its experimental ovarian cancer drug did not show statistically significant improvement in overall survival rate in a late-stage trial.
Patients given the drug, trebananib, along with a chemotherapy agent paclitaxel, experienced overall survival of 19.3 months, compared with 18.3 months for the placebo group.
Statistically significant improvement in overall survival was the secondary goal of the trial.
The trial, TRINOVA-1, is the first of three late-stage studies to evaluate safety and effectiveness of the drug in ovarian cancer patients.
The company in 2013 reported results on the main goal of trial, where patients survived longer without the disease getting worse when compared with a placebo.
Link to the complete press release: http://reut.rs/10rAZC6
Oncology Onward: A Conversation With Penn Medicine's Dr Justin Bekelman
December 19th 2023Justin Bekelman, MD, director of the Penn Center for Cancer Care Innovation, sat with our hosts Emeline Aviki, MD, MBA, and Stephen Schleicher, MD, MBA, for our final episode of 2023 to discuss the importance of collaboration between academic medicine and community oncology and testing innovative cancer care delivery in these settings.
Listen
Trastuzumab Deruxtecan Receives FDA Approval for HER2-Positive Solid Tumors
April 5th 2024FDA granted accelerated approval to trastuzumab deruxtecan-nxki for adult patients with unresectable or metastatic HER2-positive solid tumors who received prior systemic treatment and have no satisfactory alternative treatment options.
Read More